

QIBA Ultrasound Shear Wave Speed (SWS) Biomarker Committee (BC)

Wednesday, November 9, 2022; 2 PM CT

Call Summary

In attendance

David Fetzer, MD (Co-Chair)

Stephen McAleavey, PhD (Co-Chair)

Michael André, PhD

Jeff Bamber, PhD

Peter Chang, PhD, PMP

Giovanna Ferraioli, MD

J. Brian Fowlkes, PhD

Arinc Ozturk, MD

Mark Palmeri, MD, PhD

Michelle L. Robbin, MD

Keith Wear, PhD

RSNA

Julie Lisiecki

Moderator: Dr. Fetzer

Agenda items:

- Clinically Feasible (Stage 3) planning, aka Profile feasibility testing
- Manufacturer attestation and possible solutions

Clinical Feasibility Update

- Hoping to hear back from U-Rochester and colleagues in the Boston area
- Need a better understanding of section 4 – site qualification / conformance testing
- Need help with recruiting additional sites; to include some non-academic medical centers
- Dr. Robbin to talk with UAB Physics team re: Philips scanner performance or image acquisition protocols or checklist requirements (?)
- Diversity of manufacturers amongst sites is also desirable
- Ask manufacturers to recommend sites that may be willing to participate
- Cross reference with other modality BCs at the same stage may be helpful

Manufacturer Attestation

- The BC has not yet reached consensus regarding manufacturer requirements
- Section 4 – reviewed details / meaning with regard to sonographer's qualification and implications for the site
- Proper scale to gauge phantom weight with high accuracy needed
 - For reference, PEQUS phantoms are about 2 kilos
 - Suggested use of a calibrated kitchen scale
- Is a definition of sensitivity for temperature of probe, phantom, etc. needed or is a basic protocol sufficient?
- Each site should create and maintain their own protocol to be followed longitudinally
- Differentiate between manufacturer and site level
 - Realistic tolerances
 - Reasonable site requirements
 - Check with Dr. Ted Lynch (CIRS) re: temperature dependence
- Definition of a site to remain fluid for protocol that includes spot-checking sites – template needed
- Transducer and system variability discussed
 - Are transducers interchangeable?
 - Multiple combinations add variability
- Consider random spot checks
 - Testing every imaging system is not feasible
 - One site may encompass multiple systems/platforms
- Need to determine how to define site, (e.g., same sonographers, protocols, radiologists, and QA programs to be considered single site / organization)
- Another variable is using transducers that may not match the system manufacturer
- Want to create a manufacturer conformance statement with an easy-to-use QIBA template
- Dr. Fowlkes suggested manufacturers keep statements of conformance updated on their respective websites, using a QIBA template that includes recommended system settings, modes, transducers, software

Action items (new and ongoing):

- Dr. Ozturk volunteered to draft a QIBA template for manufacturers
- Dr. McAleavey to submit a [Public Comment Resolution document](#) for wiki posting and update the appendices
- Revisit wording in the checklist re: phantom QC
- BC to clarify what is meant by pre-delivery, delivery, and install, as it relates to an ultrasound system, hardware/software upgrades, and/or even new transducers
- BC to add explicit transducer requirements – perhaps not the same actual physical transducer, but the same type, e.g., 5C1 for each use
- Follow up re: QIBA oversight re: delivery of new software versions (with regard to checklist)
- Manuscript on the SWS Profile to be submitted to the *Journal of Ultrasound in Medicine (JUM)* in progress

Action items (feasibility testing):

- Recruitment beyond local or affiliated sites needed to obtain at least three volunteer sites to implement Profile and provide feedback regarding feasibility of performing requirements on a routine basis
 - Medical physicist at UT Southwestern Medical Center have agreed to participate
 - Unofficial buy-in at University of Rochester (NY)
 - Dr. Ozturk to reach out to network colleagues in Boston
- Discrepancies between Profile requirements and checklist need to be identified
- Reminder that this is not clinical confirmation; it is a practicality assessment
- Consensus was that 1 representative device from each manufacturer that a performance site may have that is performing elastography

QIBA Process Committee feasibility notes:

- All Profile procedures and requirements have been performed/checked on at least two vendor platforms and at three or more sites and found to be clear and not burdensome/impractical
 - Group consensus was that one sonographer per site could provide checklist feedback
 - One-two vendor platforms tested per site would be a useful representation of the entire site
- "External" sites should be recruited to bring "fresh eyes" to better assess the clarity of the Profile and bring different assumptions about routine practice for this biomarker
- At least one of each Profile actor have demonstrated conformance (met all requirements)
- Process links: <http://qibawiki.rsna.org/index.php/Process>

Next call – *Wednesday, January 11th at 2 pm CT {2nd Wednesdays of the month}*

[QIBA Dashboard](#) for updates